目的 探讨弥可保联合前列地尔注射液治疗糖尿病周围神经病变的临床疗效和安全性.方法 应用随机数字表法将2010年5月～2012年5月在我院内分泌代谢科收治的118例糖尿病周围神经病变患者分为A组和B组,A组患者给予弥可保进行治疗,而B组患者则给予弥可保联合前列地尔注射液进行治疗,两组患者其他治疗措施相同,治疗2周,观察并比较两组患者临床疗效和不良反应.结果 B组患者治疗总有效率为96.61%,A组患者治疗总有效率为86.44%,B组患者的治疗总有效率明显高于A组患者(P ＜ 0.05),两组患者均未见明显不良反应.结论 弥可保联合前列地尔注射液是治疗糖尿病周围神经病变的一种安全高效的方法,值得临床推广应用.%Objective To investigate the clinical efficacy and safety of Methycobal combined with Alprostadil Injection for patients with diabetic peripheral neuropathy. Methods The clinical data of one hundred and eighteen patients with diabetic peripheral neuropathy who were treated in the endocrinology department of our hospital from May 2010 to May 2012 were collected, then patients were divided into group A and group B by using a random number table, patients in group A were given Methycobal, but patients in group B were given Methycobal combined with Alprostadil Injection, other measures of the two groups were the same, after two weeks, the clinical efficacy and adverse reactions of two groups were evaluated. Results After two weeks, the total efficient rate was higher in group B than that in group A (96.61% vs 86.44%, P < 0.05), and both groups had no obvious adverse reactions. Conclusion The efficacy of patients with diabetic peripheral neuropathy by Methycobal combined with Alprostadil Injection is safe and reliable, which is worthy of clinical application.
展开▼
